Dinghang pharmaceutical and HTG molecular diagnostics signed a cooperation agreement to jointly develop new technologies of tumor immunotherapy

August 3, 2018 / Meitong news agency / -- oncologie, an innovative Biomedical Company based in Boston, USA and Shanghai, China, and HTG molecular, a NASDAQ listed company and a leading global companion diagnostic developer Diagnostics (HTG) announced recently that the two sides have completed the signing of the cooperation agreement, and will work together to develop its unique concomitant diagnosis products for the tumor immunotherapy pipeline of dinghang pharmaceutical, so as to improve the therapeutic effect of immunotumor drugs and greatly improve the long-term survival rate of specific population "It's a great honor to cooperate with dinghang Pharmaceutical Co., Ltd to develop the accompanying diagnosis project for its tumor immune innovative drug pipeline products We continue to focus on innovative drugs based on biomarkers and have a long-term interest in the field of tumor immunotherapy " According to T.J Johnson, chief executive of HTG, "based on the development of innovative drugs with specific concomitant diagnosis assistance, patients can be accurately selected, clinical efficacy can be greatly improved, and more accurate and better treatment methods can be provided for cancer patients." "The research team of dinghang pharmaceutical has developed a set of its own biomarker system, which can help doctors select suitable therapeutic drugs for cancer patients by analyzing the expression level of hundreds of genes in patients' stromal cells The system has been preliminarily verified and applied for a global patent." Added Dr Laura Benjamin, CEO of dinghang pharmaceutical "We are very honored to cooperate with HTG to turn our research work into a companion diagnostic product for the global market HTG is helping several multinational pharmaceutical enterprises around the world to develop similar products for tumors We firmly believe that HTG's technology platform and method development ability can effectively support the clinical development of dinghang medicine, so as to ultimately provide better services for tumor patients around the world Innovative drugs " Dinghang pharmaceutical and HTG developed this companion diagnostic product in the United States and China at the same time About HTG HTG, a company with the mission of precision medicine and focusing on the second generation sequencing (NGS) platform biomolecular characterization technology, it can realize complex molecular characterization of trace liquid or solid biological samples through its own intellectual property HTG edgeseq automation technology platform Many customers of HTG use this technology platform to identify biomarkers for the development of new precision medical clinical programs, thus bringing new treatment methods to patients About oncologie, located in Boston, USA and Shanghai, China, dinghang pharmaceutical is committed to developing new tumor immunotherapy drugs for cancer patients in China and the world Through cooperation with several leading biotechnology companies in the world, dinghang pharmaceutical has built a number of tumor immunotherapy product pipelines in the middle and later stage of clinical research Through technological innovation, dinghang pharmaceutical products can greatly improve the clinical success rate and provide more accurate treatment methods for patients The multi center clinical trials carried out in China and around the world by dinghang pharmaceutical will enable Chinese patients to obtain international advanced treatment methods as soon as possible.